Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...
First patient enrolled in the Phase 3 CHONQUER clinical trial in patients with IDH1-mutant conventional chondrosarcoma Phase 3 PyramIDH clinical trial in patients with IDH1-mutant myelodysplastic ...
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or ...
Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...
Alembic has received tentative approval from the Food and Drug Administration for Ivosidenib Tablets, 250 mg, which is the generic of Servier’s Tibsovo. Ivosidenib is an isocitrate dehydrogenase-1 ...
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation. In conjunction with ivosidenib’s approval, the FDA also approved ...
The US Food and Drug Administration (FDA) has approved tablets of ivosidenib (Tibsovo, Servier Pharmaceuticals) for adults with isocitrate dehydrogenase (IDH)-1 mutated relapsed or refractory ...
BOSTON, Oct. 24, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced the U.S. Food and Drug Administration (FDA) ...
BOSTON, Oct. 24, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced the U.S. Food and Drug Administration (FDA) ...
About TIBSOVO® (ivosidenib tablets) TIBSOVO is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). TIBSOVO is approved in five indications ...
Credit: Getty Images. Findings showed an objective response rate of 83.3% with 38.9% of patients having a complete response. The Food and Drug Administration (FDA) has granted Priority Review for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results